HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could low-dose radiation boost cancer treatment before surgery?
Disease control CompletedThis study compares two treatment approaches for people with operable head and neck squamous cell carcinoma. One group receives low-dose radiotherapy plus targeted therapy and immunotherapy before surgery, while the other gets only targeted therapy and immunotherapy. The goal is …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested whether giving the immunotherapy drug durvalumab alongside radiation works better than the standard cetuximab plus radiation for people with advanced head and neck cancer who cannot take the usual chemotherapy drug cisplatin. A total of 196 adults took part. The…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New chemo combo shows promise for head and neck cancer before surgery
Disease control CompletedThis phase 2 trial tested two chemotherapy drugs, paclitaxel and carboplatin, given before surgery to 79 people with locally advanced head and neck cancer. The goal was to see how well the drugs shrink tumors before surgery. The main measure was a major pathologic response, meani…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental drug aims to supercharge immune system before cancer surgery
Disease control CompletedThis early-phase study tested a single dose of an experimental antibody (MEDI0562) given before surgery to 13 patients with advanced head and neck cancer or melanoma. The goal was to see if the drug safely activates the immune system to fight the cancer. Researchers compared givi…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental 'In-Situ' vaccine aims to train immune system against three cancers
Disease control CompletedThis early-phase trial tested a combination of four therapies to see if they could safely boost the immune system to fight cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head & neck cancer received low-dose radiation and two immune-boosting drugs inje…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Triple threat: vaccine, immunotherapy, and Chemo-Radiation take on HPV head and neck cancer
Disease control CompletedThis phase 2 trial tested a new approach for people with intermediate-risk HPV-related head and neck cancer. Participants received an HPV-16 vaccine (ISA101b) plus the immunotherapy drug pembrolizumab alongside standard chemoradiation. The goal was to see if this combination coul…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug combo shows promise against tough head and neck cancer
Disease control CompletedThis study tested a combination of two drugs, ramucirumab and pembrolizumab, in 43 people with head and neck cancer that had spread or come back. The goal was to first find a safe dose and then see if the combination could shrink tumors. The approach aims to block blood vessel gr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Yeast vaccine shows promise in stopping Cancer's return
Disease control CompletedThis early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NantBioScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Immunotherapy after second surgery shows promise for tough head and neck cancers
Disease control CompletedThis study tested the drug nivolumab (Opdivo) in 39 people with head and neck cancer who had already received radiation and then had a second surgery to remove remaining cancer. The goal was to see if nivolumab could help prevent the cancer from coming back and to check for side …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis phase 3 trial tested whether adding lenvatinib (Lenvima) to pembrolizumab (Keytruda) works better than pembrolizumab alone for people with recurrent or metastatic head and neck squamous cell carcinoma. The study enrolled 511 participants whose tumors express PD-L1. Researche…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo shows promise against tough head and neck cancer
Disease control CompletedThis study tested a treatment plan for people with advanced head and neck cancer that cannot be removed by surgery. The plan combined the immunotherapy drug camrelizumab with chemotherapy and radiation. 39 adults took part. The goal was to see if the treatment could help control …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New vaccine combo shows promise in advanced cancers
Disease control CompletedThis phase 2 trial tested a new cancer vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The study enrolled 63 participants to see if the combination is safe a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: IO Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental combo aims to supercharge cancer immunotherapy
Disease control CompletedThis early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Double-Drug attack shows promise for tough head and neck cancers
Disease control CompletedThis study tested whether combining two FDA-approved cancer drugs, cetuximab and nivolumab, could help people with advanced head and neck cancer that has returned or spread. A total of 95 participants received the drug combination to find the best dose and see if it improves surv…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New cancer combo drug tested in tiny safety study
Disease control CompletedThis early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis Phase 3 trial tested whether adding lenvatinib to pembrolizumab (Keytruda) helps people with recurrent or metastatic head and neck squamous cell carcinoma that has a specific marker (PD-L1). The study enrolled 112 participants and compared the combination against pembrolizum…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New biosimilar RPH-002 takes on erbitux in head and neck cancer trial
Disease control CompletedThis Phase 1 trial compared a new biosimilar drug, RPH-002, to the standard cancer drug Erbitux in 118 patients with advanced head and neck cancer that could not be removed by surgery. The main goals were to see if RPH-002 reaches similar levels in the blood and has a similar saf…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
AI shrinks radiation target, cuts side effects in head and neck cancer
Disease control CompletedThis study tested a new way to give radiation for head and neck cancer. Instead of treating the whole neck, doctors used artificial intelligence to focus radiation only on the cancer spots. 67 patients took part to see if this approach could reduce side effects without increasing…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Cialis and keytruda together against head and neck cancer: small trial shows promise?
Disease control CompletedThis completed phase II study tested a combination of two drugs—tadalafil (Cialis) and pembrolizumab (Keytruda)—in 7 adults with advanced head and neck cancer that had spread or come back. The goal was to see if the combination was safe and could help control the disease. Because…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New cancer pill tested in humans for first time
Disease control CompletedThis early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Godavari Biorefineries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
First human trial of BI 765049 combo aims to fight hard-to-treat cancers
Disease control CompletedThis early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 people with advanced head and neck cancer that had returned or spread. The goal was to see if the combination could shrink tumors or slow the disease. Participants were grouped based on whether they …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Supercharged immune cells take on Hard-to-Treat head and neck cancer
Disease control CompletedThis trial tested a new treatment for people with Epstein-Barr virus (EBV)-positive head and neck cancer that has spread or come back. The treatment uses specially engineered immune cells (TCR-T cells) that recognize EBV on cancer cells and also release a PD1 blocker to help them…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take aim at HPV-Positive cancers
Disease control CompletedThis early-stage trial tested a new type of cell therapy for people with HPV-positive head & neck or cervical cancer. The treatment uses a patient's own immune cells, engineered to recognize and attack HPV-infected cancer cells. Some patients also received cells that produce an a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill JAB-3312 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Triple therapy shrinks head and neck tumors before surgery in early trial
Disease control CompletedThis early-phase study tested a combination of low-dose radiation, an immunotherapy drug (tislelizumab), and a targeted therapy (afatinib) given before surgery to people with head and neck cancer. The main goal was to find a safe dose and see how well the treatment shrinks tumors…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: I-Mab Biopharma US Limited • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Your own tumor cells could be the key to fighting cancer
Disease control CompletedThis early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a lung cancer drug boost chemo for head and neck tumors?
Disease control CompletedThis phase 2 study tested whether adding the drug erlotinib to standard chemotherapy (docetaxel plus cisplatin or carboplatin) helps shrink head and neck tumors before surgery. 55 patients with advanced but operable head and neck cancer took part. The main goal was to see how man…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Neck surgery before Chemo-Radiation may reduce side effects in head and neck cancer patients
Disease control CompletedThis study looked at 65 people with advanced head and neck cancer that had spread to lymph nodes. It compared two approaches: having surgery to remove affected lymph nodes before chemo-radiation, versus chemo-radiation alone. The goal was to see if upfront surgery could reduce tr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Smarter radiation dosing aims to cut side effects for head and neck cancer patients
Disease control CompletedThis study tested a new way of giving radiation to people with head and neck cancer. The goal was to lower the radiation dose to healthy neck areas to reduce side effects like trouble eating, while still keeping the cancer from coming back. About 300 patients took part, and the r…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo shows promise in Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested whether adding the drug buparlisib to standard chemotherapy (paclitaxel) helps people with advanced head and neck cancer live longer. About 487 adults whose cancer had returned or spread and who had already tried other treatments took part. The goal was to see i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug BDB001 tested in patients whose tumors resisted standard immunotherapy
Disease control CompletedThis study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Fluoride shield: new hope for cancer Patients' teeth
Disease control CompletedThis pilot study tested whether applying prescription fluoride varnish to teeth every three months during the first year after radiation therapy for head and neck cancer can reduce cavities and gum problems. 13 adults with at least 4 natural teeth and certain cancers took part. T…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New immunotherapy DF9001 targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or returned. The goal was to see if the combo could shrink tumors better than standard treatments. Participants ha…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer cocktail shows promise in early human trial
Disease control CompletedThis early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can a tailored Stop-Smoking program help cancer patients quit?
Disease control CompletedThis study tested an enhanced tobacco intervention program (ETIP) for people with head and neck or lung cancer who smoke. The program combined counseling, nicotine replacement, and medications like bupropion or varenicline. Nineteen participants were enrolled to see if the progra…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 26, 2026 14:44 UTC
-
Breath sniffing device may spot head and neck cancer early
Diagnosis CompletedThis study tested a device called an 'artificial nose' that analyzes breath to detect head and neck cancer. 45 people (some with cancer, some healthy) gave breath samples. The device used sensors to create a unique breath pattern, aiming to tell who had cancer and who did not.
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New MRI scan could spot returning head and neck cancer early
Diagnosis CompletedThis study tested whether a special type of MRI (diffusion-weighted MRI) can predict if head and neck cancer will come back after chemoradiotherapy. Fifty-nine patients had two MRIs: one before treatment and one three months after. The goal was to see if changes in water movement…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: CHU de Reims • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Pre-Treatment workouts may boost strength in head and neck cancer patients
Symptom relief CompletedThis study tested whether a short exercise program before chemoradiotherapy helps head and neck cancer patients maintain physical function. 47 adults with head and neck cancer were randomly assigned to either an exercise prehabilitation group or usual care. The exercise program l…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Associacao de Investigacao de Cuidados de Suporte em Oncologia • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Common drug may shield kidneys from chemo harm
Symptom relief CompletedThis study tested whether pentoxifylline, a drug used for blood flow problems, can protect the kidneys from damage caused by cisplatin chemotherapy in head and neck cancer patients. 90 adults receiving cisplatin for the first time took part. Researchers measured kidney injury usi…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Tanta University • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Radiation's hidden toll: study tracks tooth loss in cancer survivors
Knowledge-focused CompletedThis study follows head and neck cancer patients who received radiation therapy to see how many teeth they lose over two years. It also looks at other mouth problems like dry mouth and bone damage. The goal is to better understand and manage these long-term side effects.
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Microdose drug test aims to find best cancer fighters
Knowledge-focused CompletedThis early-phase study tested very small amounts of several cancer drugs (rilvegostomig, volrustomig, sabestomig, AZD9592, and pembrolizumab) injected directly into head and neck tumors in 17 people. The goal was to see how each drug affects the tumor's environment at the injecti…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Presage Biosciences • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Gut bacteria cocktail tested as cancer treatment booster
Knowledge-focused CompletedThis study tested whether a defined mixture of live gut bacteria from a healthy donor (MET-4) is safe and can be detected in patients with advanced oropharyngeal cancer receiving standard chemoradiation. Thirty participants took the bacteria by mouth daily for up to four weeks. T…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New imaging technique could help doctors predict cancer treatment response
Knowledge-focused CompletedThis study tested whether a PET scan using a tracer called FMISO can measure oxygen levels (hypoxia) in head and neck cancers. Sixteen patients received the scan before starting radiotherapy. The goal was to see if the amount of hypoxia seen on the scan could predict how well the…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
AI analyzes 10,000 patient records to predict head and neck cancer recurrence
Knowledge-focused CompletedThis completed study used artificial intelligence to examine electronic health records from 10,000 head and neck cancer patients. The goal was to create models that can predict the risk of cancer coming back or progressing, and to identify which patients might live longer after i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Savana Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
App aims to catch Quality-of-Life drops early in head and neck cancer survivors
Knowledge-focused CompletedThis completed trial tested a mobile app and web platform (BD4QoL) to monitor quality of life in 410 head and neck cancer survivors after curative treatment. The goal was to see if the platform could reduce or catch early declines in quality of life compared to standard follow-up…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Custom DNA blood test could spot head and neck cancer return
Knowledge-focused CompletedThis study tested a personalized blood test that looks for tumor DNA in 40 patients with advanced head and neck cancer. The goal was to see if the test could help predict how the disease will progress and detect if the cancer comes back after treatment. Researchers took blood sam…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New blood test could replace invasive cancer biopsies
Knowledge-focused CompletedThis study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Pharmassist Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Tumor biobank holds key to personalized head and neck cancer care
Knowledge-focused CompletedThis study collected tumor samples from 419 people with head and neck cancer to create a biobank. Researchers will use these samples in future genomic studies to find factors that predict how well a person will respond to treatment. The goal is to improve personalized outcome pre…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Maastricht Radiation Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC